Heudobler, D., Luke, F., Hahn, J., Grube, M., Schlosser, P., Kremers, S., Sudhoff, T., Westermann, J., Hutter-Kronke, M. L., Schlenk, R. F., Weber, D., Paschka, P., Zeman, F., Dohner, H., Herr, W., Reichle, A. and Thomas, S. (2024) “Low-dose azacitidine, pioglitazone and all-<i>trans</i&gt; retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase”, Haematologica. Pavia, Italy, 109(4), pp. 1274-1278. doi: 10.3324/haematol.2023.283864.